Posted by Michael Wonder on 22 Nov 2021
TGA grants provisional determination to Grand Pacific for its COVID-19 protein-based subunit vaccine
22 November 2021 - The Therapeutic Goods Administration has granted provisional determination to Grand Pacific CRO (the Australian sponsor acting on behalf of Medigen Vaccine Biologics) in relation to its COVID-19 vaccine: MVC-COV1901-S-2P-Protein (MVC-COV1901 Vaccine).
This protein-based subunit vaccine will be considered for the active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals aged 18 years of age and older. If approved, a complete course of the MVC-COV1901 Vaccine is likely to be two doses given as an injection 4 weeks apart.
